Sensitivity of the Elecsys Nucleocapsid Assay for the Detection of Preceding SARS-CoV-2 Infections
Brian Grunau, Janessa Tom, Michael Asamoah-Boaheng, Sheila F. O’Brien, Steven J. Drews, Sadaf Sediqi, Pascal M. Lavoie, Vilte Barakauskas, David A. Goldfarb
Abstract
Nucleocapsid serological assay sensitivity to identify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections among vaccinees and for Omicron cases is unclear. In this prospective study, the Elecsys nucleocapsid assay was 89% sensitive in identifying SARS-CoV-2 infections 14-607 days pre-blood collection. Sensitivity was similar when comparing by vaccination status, and in Omicron (vs pre-Omicron) cases.
Topics & Concepts
MedicineVirologySensitivity (control systems)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakOutbreakInternal medicineInfectious disease (medical specialty)DiseaseElectronic engineeringEngineeringSARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testingBiosensors and Analytical Detection